Growth Metrics

Novartis Ag (NVS) EPS (Basic) Growth (1y) (2010 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 169.38%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -52.52%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -45.83%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -185.57%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 4.66%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 53.77%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -7.69%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 8.26%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -100.00%
Dec 31, 2024 3,716.45%
Jun 30, 2024 2,416,048,109,865.64%
Dec 31, 2023 223.28%
Sep 30, 2023 -22.39%
Jun 30, 2023 -100.00%
Mar 31, 2023 21,378,151,160.50%
Dec 31, 2022 -97.33%
Sep 30, 2022 15,918,498,226.99%
Jun 30, 2022 107,751,742,722.22%
Mar 31, 2022 17.30%
Dec 31, 2021 22.52%
Sep 30, 2021 7.71%
Jun 30, 2021 -56.50%
Mar 31, 2021 171.62%
Mar 31, 2020 293.72%
Mar 31, 2019 -278.75%
Dec 31, 2018 -105.20%
Sep 30, 2018 -100.00%
Jun 30, 2018 -99.56%
Mar 31, 2018 -100.00%
Dec 31, 2017 -93.32%
Sep 30, 2017 10.72%
Jun 30, 2017 687.41%
Mar 31, 2017 243.28%
Dec 31, 2016 392,527.66%
Sep 30, 2016 551.92%
Jun 30, 2016 1,477,777,877.78%
Mar 31, 2016 40,258,390.80%
Dec 31, 2015 984.13%
Sep 30, 2015 81,729,095.89%
Jun 30, 2015 63.96%
Mar 31, 2015 4.13%
Sep 30, 2014 13.88%
Jun 30, 2014 -73.55%
Sep 30, 2013 -79.35%
Jun 30, 2013 -113.02%
Sep 30, 2012 7.89%
Jun 30, 2012 -41.42%
Mar 31, 2012 -100.00%
Dec 31, 2011 121.50%
Sep 30, 2011 -12.78%
Jun 30, 2011 12.21%
Mar 31, 2011 -78.47%
Sep 30, 2010 53,419.41%
Jun 30, 2010 51,619,396.86%
Mar 31, 2010 273,543.41%